HBIO
Harvard Bioscience, Inc.
HBIO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
HBIO's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
HBIO PE Valuation
HBIO has no meaningful PE right now: it lost money over the past year.
HBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect HBIO's losses to shrink, with revenue growing.
HBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.59 | +$9.51 |
| Q2 2026 | -$2.31 | +$10.59 |
| Q1 2026 | -$2.17 | +$10.93 |
| Q4 2025 | -$12.80 | -$10.00 |
| Q3 2025 | -$12.10 | -$8.80 |
| Q2 2025 | -$12.90 | -$10.40 |
| Q1 2025 | -$13.10 | -$11.10 |
| Q4 2024 | -$2.80 | -$2.00 |
HBIO is still losing money, but far less than before: $2.59 per share over the past year, against $13.10 at its worst in early 2025.
HBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.2M | +7.8% |
| Q2 2026 | $22.7M | +11% |
| Q1 2026 | $20.8M | -4.7% |
| Q4 2025 | $23.7M | -3.3% |
| Q3 2025 | $20.6M | -6.3% |
| Q2 2025 | $20.5M | -11% |
| Q1 2025 | $21.8M | -11% |
| Q4 2024 | $24.6M | -13% |
HBIO's revenue is recovering but still below its 2021 peak: $22M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.2% | -6.1 points |
| Q2 2026 | -4.3% | -0.3 points |
| Q1 2026 | -5.7% | +223 points |
| Q4 2025 | 7.2% | +7.2 points |
| Q3 2025 | 1% | +9.5 points |
| Q2 2025 | -4% | +5 points |
| Q1 2025 | -228% | -219 points |
| Q4 2024 | 0% | -1 points |
HBIO's operating margin was −5.2% last quarter, down 6.1 points from the same quarter a year ago.
HBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2M | -234% |
| Q2 2026 | -$363K | -114% |
| Q1 2026 | -$1.1M | -144% |
| Q4 2025 | -$545K | -138% |
| Q3 2025 | $877K | +$2.6M |
| Q2 2025 | $2.7M | +$4.3M |
| Q1 2025 | $2.5M | +226% |
| Q4 2024 | $1.4M | -59% |
HBIO's free cash flow has turned negative after years in the green: −$3M over the past year.
HBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +35K shares |
| 1 year | +2.4% | +105K shares |
| 3 years | +6.8% | +292K shares |
| 5 years | +15% | +582K shares |
| Available history | +21% | +780K shares |
HBIO has 5M diluted shares, up 2.4% from a year ago.
HBIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.3x | High |
| Q2 2026 | 6.2x | High |
| Q1 2026 | 5.5x | High |
| Q4 2024 | 43.1x | High |
| Q3 2024 | 30.5x | High |
| Q2 2024 | 15.6x | High |
| Q1 2024 | 6.5x | High |
| Q4 2023 | 3.7x | Elevated |
HBIO's net debt is about 10 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
HBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 83.0 | Overbought |
HBIO's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
HBIO PE vs Healthcare Sector
HBIO has no meaningful PE right now: it lost money over the past year.
HBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.42 | 9.4% above |
| 20 week MA | $7.52 | 22% above |
| 50 week MA | $6.58 | 40% above |
| 100 week MA | $7.00 | 32% above |
| 200 week MA | $23.1 | 60% below |
HBIO has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 60% below its 200-week average.
HBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.4 | $40.8 | +39% |
| 2021 | $40.8 | $71.0 | +74% |
| 2022 | $71.0 | $27.3 | -62% |
| 2023 | $27.3 | $53.5 | +96% |
| 2024 | $53.5 | $19.8 | -63% |
| 2025 | $19.8 | $7.02 | -65% |
| 2026 YTD | $7.02 | $9.21 | +31% |
HBIO is up 31% so far in 2026, after finishing lower in three of the previous six years.